Celyad Oncology SA (CYAD) Financials

NASDAQ Currency in USD Disclaimer

$0.00

Last update: 07:00 PM EST
Day's range
$0
Day's range
$0
$10M$10M$0$0-$10M-$10M-$20M-$20M-$30M-$30M-$40M-$40M-$50M-$50M-$60M-$60MEarning201720172018201820192019202020202021202120222022202320230%0%-100000%-100000%-200000%-200000%-300000%-300000%-400000%-400000%-500000%-500000%-600000%-600000%-700000%-700000%Profit Margin
Profit Margin
Revenue
Earnings

CYAD Income statement / Annual

Last year (2023), Celyad Oncology SA's total revenue was $102.00 K, and the percentage change from the previous year is not available. In 2023, Celyad Oncology SA's net income was -$8.45 M. See Celyad Oncology SA,s key income statements, including revenue, expenses, profit, and income.

Period FY-2023 FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016 FY-2015 FY-2014
Period Ended 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Operating Revenue $102.00 K $0.00 $0.00 $5.00 K $6.00 K $3.12 M $3.54 M $8.52 M $3.00 K $146.00 K
Cost of Revenue $69.00 K $1.44 M $1.52 M $0.00 $0.00 $0.00 $515.00 K $53.00 K $6.38 M $115.00 K
Gross Profit $33.00 K -$1.44 M -$1.52 M $5.00 K $6.00 K $3.12 M $3.03 M $8.47 M -$6.38 M $31.00 K
Gross Profit Ratio 0.32 0 0 1 1 1 0.85 0.99 -2126.33 0.21
Research and Development Expenses $4.67 M $18.93 M $20.77 M $21.59 M $25.23 M $23.58 M $22.91 M $27.68 M $5.90 M $15.87 M
General & Administrative Expenses $5.71 M $10.34 M $9.67 M $9.00 M $8.73 M $10.39 M $9.31 M $9.74 M $7.23 M $5.02 M
Selling & Marketing Expenses $215.00 K $239.00 K $434.00 K $454.00 K $607.00 K $676.00 K $761.00 K $728.00 K $891.00 K $394.00 K
Selling, General & Administrative Expenses $6.25 M $10.34 M $9.67 M $9.00 M $8.73 M $10.39 M $9.31 M $9.74 M $7.23 M $5.02 M
Other Expenses -$2.43 M -$9.00 M -$3.53 M -$4.34 M -$4.58 M $7.32 M -$23.79 M -$2.52 M -$222.00 K -$963.00 K
Operating Expenses $8.49 M $20.26 M $26.91 M $26.24 M $29.38 M $41.29 M $29.63 M $34.08 M $29.68 M $19.92 M
Cost And Expenses $8.56 M $20.26 M $26.91 M $26.24 M $29.38 M $41.29 M $30.14 M $34.13 M $29.68 M $20.03 M
Interest Income $30.00 K $12.00 K $27.00 K $51.00 K $92.00 K $804.00 K $933.00 K $2.20 M $542.00 K $277.00 K
Interest Expense $84.00 K $197.00 K $255.00 K $297.00 K $343.00 K $62.00 K $4.45 M $207.00 K $236.00 K $22.00 K
Depreciation & Amortization $794.00 K $1.44 M $1.52 M $1.83 M $1.79 M $1.11 M $1.71 M $1.52 M $1.03 M $870.00 K
EBITDA -$7.76 M -$39.70 M -$25.41 M -$15.73 M -$27.45 M -$36.56 M -$55.70 M -$21.99 M -$28.07 M -$15.32 M
EBITDA Ratio -76.11 0 0 -3146.4 -4575 -11.74 -15.73 -2.58 -9357 -104.9
Operating Income Ratio -82.91 0 0 -5247.8 -4895.5 -12.25 -14.94 -3 -9890.67 -112.58
Total Other Income/Expenses Net -$54.00 K -$13.00 K -$111.00 K -$217.00 K $239.00 K $433.00 K -$3.52 M $2.00 M $558.00 K -$16.00 K
Income Before Tax -$8.51 M -$40.87 M -$26.50 M -$17.20 M -$28.64 M -$37.43 M -$56.40 M -$23.61 M -$29.11 M -$16.45 M
Income Before Tax Ratio -83.44 0 0 -3440.8 -4773.33 -12.02 -15.93 -2.77 -9704.67 -112.69
Income Tax Expense -$191.00 K $65.00 K $10.00 K $297.00 K -$8.00 K -$1.11 M -$1.00 K -$6.00 K -$55.00 K -$2.48 M
Net Income -$8.45 M -$40.94 M -$26.51 M -$17.50 M -$28.63 M -$36.31 M -$56.40 M -$23.61 M -$29.11 M -$16.45 M
Net Income Ratio -82.82 0 0 -3500.2 -4772 -11.66 -15.93 -2.77 -9704.67 -112.69
EPS -0.33 -1.81 -1.7 -1.26 -2.29 -3.26 -5.86 -2.53 -3.43 -2.44
EPS Diluted -0.33 -1.81 -1.7 -1.26 -2.29 -3.26 -5.86 -2.53 -3.43 -2.44
Weighted Average Shares Out $25.72 M $22.59 M $15.60 M $13.94 M $12.52 M $11.14 M $9.62 M $9.31 M $8.48 M $6.75 M
Weighted Average Shares Out Diluted $25.72 M $22.59 M $15.60 M $13.94 M $12.52 M $11.14 M $9.62 M $9.33 M $8.49 M $6.75 M
Link